Evidence

Cost-effectiveness of 70-gene MammaPrint Signature in Node-Negative Breast Cancer

December 21, 2010

PUBLICATION: Am J Manag Care. 2010 Dec 1;16(12):e333-42. AUTHORS: Chen E., Tong K.B., Malin J.L. SUMMARY: 70-gene signature reclassified 29% of patients and spared 10% of patients from chemotherapy. Results of this modeling analysis suggest that treatment guided by 70-gene signature may be associated with a decrease in chemotherapy use and an increase in life expectancy when applied…

Read more